The Mexican government signed a purchase agreement for Pfizer’s oral antiviral therapy against Covid-19, which contemplates the acquisition of 300,000 oral treatments that have already begun to arrive in the country.
The president of the laboratory, Constanza Losada, assured that the fight and commitment to end the effects of the pandemic is everyone’s taskso this reflects the objective of continuing to seek the well-being of people
“This agreement helps us to continue working hand in hand with the Government of Mexico and thus achieve our shared goal of addressing this public health crisis.
Read: Novavax’s Covid-19 vaccine must carry a warning about side effects on the heart: EMA
According to the company, the antiviral treatment, focused on administering to people who have the disease caused by the SARS-CoV-2 virus and who are at high risk of developing complications, was approved by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS). ) last January 2022, being the first health regulatory agency in Latin America to approve it, and the second country in the region to be supplied.
Pfizer’s treatment includes Nirmatrelvir, a novel protease inhibitor that was specifically designed to block the activity of SARS-CoV-2 protease 3CL, an enzyme that the coronavirus needs to replicate.
The data show that this treatment reduces the risk of hospitalization or death by 89% (when started within three days of the onset of symptoms) and by 88% (when started within the fourth to fifth day after the onset of symptoms). onset of symptoms) compared to placebo.
Follow us on Google News to always stay informed